Nathan J. Dowden, Chief Operating Officer at Entrada Therapeutics, Inc. (TRDA), sold 10,994 shares at $18.05 ($198K) on 2023-07-11, disclosed to the SEC on 2023-07-12.
Scheduled sale ($198k) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.00 | 3,200 | $58K | 29.0% |
| 2 | $18.05 | 3,897 | $70K | 35.5% |
| 3 | $18.05 | 3,897 | $70K | 35.5% |
| Total | $18.04 avg | 10,994 | $198K | 100% |
| Filing → |
| TRDA | SELL | 2024-09-30 | $14K | — | Filing → |
| TRDA | SELL | 2024-09-10 | $35K | — | Filing → |
| TRDA | SELL | 2024-08-20 | $873K | — | Filing → |